Response to neoadjuvant therapy (Core)

Several grading systems for histopathological tumour response to neoadjuvant therapy have been applied to treated gastrointestinal carcinomas. These include the Mandard,[1] Becker,[2] Japanese Gastric Cancer Association (JGCA)[3] and College of American Pathologists (CAP)[4]/ American Joint Committee on Cancer (AJCC)[5] tumour regression grading schemes.[6,7] While the Mandard system[1] is based on the fibrosis/tumour ratio (Table 4), the four-tiered Becker system[2] uses the estimated percentage of residual tumour in relation to the (assumed) previous tumour size (Table 5). The CAP modified Ryan grading system,[8] which is also referred to by the AJCC Staging System 8th Edition,[5] is shown in Table 6.

Table 4: Mandard tumour regression grading system.[1]

Description	Tumour Regression Score
Complete regression: fibrosis without detectable tumour	1
Fibrosis with rare, scattered residual cancer cells	2
Fibrosis and tumour cells with a predominance of fibrosis	3
Fibrosis and tumour cells with predominance of tumour cells	4
No signs of regression	5

Table 5: Becker Tumour Regression Grading System.[2]

Description	Tumour Regression Score
No residual carcinoma	1
1-10% residual carcinoma	2
11-50% residual carcinoma	3
>50% residual carcinoma	4

Table 6: College of American Pathologists modified Ryan tumour regression grading system.[4]

Description	Tumour Regression Score
No viable cancer cells (complete response)	0
Single cells or rare small groups of cancer cells (near complete response)	1
Residual cancer with evident tumour regression, but more than single cells or rare small groups of cancer cells (partial response)	2
Extensive residual cancer with no evident tumour regression (poor or no response)	3

Reproduced with permission from Ryan R et al (2005). Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology* 47(2):141-146.[8]

Although many studies[6,9-11] have evaluated and compared these schemes in assessing treatment response in gastrointestinal carcinomas after neoadjuvant therapy, there is no consensus on the optimal method to stratify tumour regression. In addition, the inter- and intra-observer variability is high in most schemes. Nevertheless, response to neoadjuvant therapy should be reported, as assessment of histological tumour regression may provide valuable prognostic information and may impact on the choice of postoperative therapy.[6] Patients with complete tumour regression have

significantly better overall survival compared to patients with residual adenocarcinoma. As there is currently no consensus, the CAP grading system, which is a modified Ryan scheme,[8] is recommended by the Carcinoma of the Stomach Dataset Authoring Committee. The CAP grading system assesses the residual tumour cells rather than treatment-associated fibrosis.

The presence of lymph node metastasis is one of the most important prognosticators in gastrointestinal carcinomas, but a method to determine tumour regression in lymph nodes has not been established. Furthermore, so far only a few studies have demonstrated that regressive changes in lymph node metastasis were associated with patient outcome.[6] Therefore, tumour regression should only be assessed in the primary tumour for the time being.

If there is no tumour visible on macroscopic examination, the entire assumed tumour bed should be processed into paraffin blocks in order to correctly stage tumours and evaluate treatment response. However, there is no standard protocol for grossing specimens with macroscopically visible residual carcinoma. Most pathologists gross these specimens similar to those without preoperative treatment. Routine cytokeratin immunohistochemistry (IHC) is not recommended, but it may be helpful, if available, when the specimen is morphologically suspicious for residual viable tumour. According to the Union for International Cancer Control (UICC)[12]/AJCC[5] 8th Edition Staging Manuals, acellular mucin pools, necrosis, and degenerative/ reactive changes without viable tumour cells after treatment should be interpreted as negative for tumour.

References

1   Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier J-M, Bonvalot S and Gignoux M (1994). Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. *Cancer* 73(11):2680-2686.

2   Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR and Hofler H (2003). Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. *Cancer* 98(7):1521-1530.

3   Sano T and Kodera Y (2011). Japanese classification of gastric carcinoma: 3rd English Edition. *Gastric Cancer* 14(2):101-112.

4   College of American Pathologists (2020). *Protocol for the examination of specimens from patients with carcinoma of the stomach*. Available from: https://documents.cap.org/protocols/cp-giupper-esophagus-20-4100.pdf (Accessed 9th October 2020).

5   Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM and Meyer LR (eds) (2017). *AJCC Cancer Staging Manual. 8th Edition*, Springer, New York.

6   Langer R and Becker K (2018). Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. *Virchows Arch* 472(2):175-186.

7   Thies S and Langer R (2013). Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. *Front Oncol* 3:262.

8   Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D and Sheahan K (2005). Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology* 47(2):141-146.

9   Donohoe CL, O'Farrell NJ, Grant T, King S, Clarke L, Muldoon C and Reynolds JV (2013). Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. *Ann Surg* 258(5):784-792.

10   Neves Filho EH, de Sant'Ana RO, Nunes LV, Pires AP and da Cunha MD (2017). Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. *Apmis* 125(2):79-84.

11   Tong Y, Liu D and Zhang J (2020). Connection and distinction of tumor regression grading systems of gastrointestinal cancer. *Pathol Res Pract* 216(9):153073.

12   Brierley JD, Gospodarowicz MK and Wittekind C (eds) (2016). *Union for International Cancer Control. TNM Classification of Malignant Tumours, 8th Edition*, Wiley-Blackwell, USA.